```mermaid
flowchart TD
CTNNB1_gene["CTNNB1<br/>Gene"]
beta_catenin["beta-Catenin<br/>Protein"]
LRP1["LRP1<br/>Receptor"]
TCF3["TCF3<br/>Transcription Factor"]
AXIN2["AXIN2<br/>Wnt Regulator"]
RRM1["RRM1<br/>DNA Repair"]
SQSTM1["SQSTM1/p62<br/>Autophagy Adapter"]
RAB7A["RAB7A<br/>Vesicle Transport"]
ALS["Amyotrophic Lateral<br/>Sclerosis (ALS)"]
MS["Multiple Sclerosis<br/>(MS)"]
neuroinflammation["Neuroinflammation"]
fibrosis["Tissue Fibrosis"]
cancer["Cancer/Tumors"]
wnt_signaling["Wnt Signaling<br/>Pathway"]
cell_adhesion["Cell Adhesion<br/>and Migration"]
synaptic_function["Synaptic Function<br/>and Plasticity"]
CTNNB1_gene -->|"encodes"| beta_catenin
LRP1 -->|"regulates"| beta_catenin
beta_catenin -->|"interacts_with"| TCF3
beta_catenin -->|"activates"| wnt_signaling
beta_catenin -->|"regulates"| cell_adhesion
beta_catenin -->|"modulates"| synaptic_function
wnt_signaling -->|"associated_with"| AXIN2
beta_catenin -->|"activates"| RRM1
CTNNB1_gene -->|"associated_with"| SQSTM1
CTNNB1_gene -->|"associated_with"| RAB7A
CTNNB1_gene -->|"regulates"| ALS
CTNNB1_gene -->|"therapeutic_target"| MS
CTNNB1_gene -->|"therapeutic_target"| neuroinflammation
CTNNB1_gene -->|"therapeutic_target"| fibrosis
CTNNB1_gene -->|"regulates"| cancer
wnt_signaling -->|"dysfunction_leads_to"| ALS
cell_adhesion -->|"impairment_causes"| neuroinflammation
synaptic_function -->|"disruption_i
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CTNNB1 — Catenin Beta 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CTNNB1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Catenin Beta 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3p22.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/1499" target="_blank">1499</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100994" target="_blank">ENSG00000100994</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/116806" target="_blank">116806</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprotkb/P35222" target="_blank">P35222</a></td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>781 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~85 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, highest in brain</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">385 edges</a></td>
</tr>
</table>
CTNNB1 (Catenin Beta 1) is a critical gene encoding beta-catenin, a multifunctional protein that serves as a key downstream effector of the canonical Wnt signaling pathway and as an essential component of the cadherin-mediated cell adhesion complex[@valenta2022]. In the central nervous system, beta-catenin plays pivotal roles in neuronal development, synapse formation, synaptic plasticity, and cognitive function. Dysregulation of Wnt/beta-catenin signaling has been strongly implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis](/diseases/als), and other neurodegenerative disorders[@macdonald2009].
The CTNNB1 gene is located on chromosome 3p22.1 and is approximately 23.5 kb in length, encoding a protein of 781 amino acids with a molecular weight of approximately 85 kDa[@huang2024]. The gene is highly conserved across species, reflecting its essential role in development and cellular function.
The CTNNB1 protein contains several functional domains that enable its diverse biological functions[@graham2000]:
N-terminal regulatory domain: Contains critical phosphorylation sites that regulate beta-catenin stability. Key residues include Ser33, Ser37, Thr41, and Ser45, which are phosphorylated by [glycogen synthase kinase 3β](/genes/gsk3b) (GSK-3β) in the absence of Wnt signaling. These phosphorylations target beta-catenin for ubiquitination and proteasomal degradation[@yost1998].
Central armadillo repeat domain: Consists of 12 armadillo repeats that mediate protein-protein interactions with various binding partners, including:
Beta-catenin uniquely functions in two distinct cellular compartments:
The canonical Wnt/beta-catenin signaling pathway is essential for embryonic development and adult brain function[@ille2005]. The pathway operates through a carefully regulated destruction complex:
In the absence of Wnt ligands: Beta-catenin is continuously phosphorylated by a destruction complex containing GSK-3β, casein kinase 1α (CK1α), AXIN, and APC. Phosphorylated beta-catenin is ubiquitinated by the β-TrCP ubiquitin ligase complex and degraded by the proteasome, maintaining low cytoplasmic levels[@macdonald2009].
When Wnt signaling is activated: Wnt ligands bind to Frizzled receptors and LRP5/6 co-receptors, triggering downstream signaling that disrupts the destruction complex. This allows beta-catenin to accumulate in the cytoplasm and translocate to the nucleus. In the nucleus, beta-catenin displaces transcriptional repressors from TCF/LEF proteins and recruits co-activators to activate target genes involved in neurodevelopment and synaptic plasticity[@nusse2012].
At synapses, beta-catenin plays crucial roles in maintaining synaptic structure and function[@bamann2007]:
Synapse formation: Beta-catenin localizes to developing synapses and regulates the recruitment of pre-synaptic components and post-synaptic density proteins. This localization is dynamic and activity-dependent, responding to neuronal activity patterns[@chen2010].
Dendritic spine morphology: Post-synaptic beta-catenin controls dendritic spine density and morphology through its interaction with PSD-95 and NMDA receptors. Loss of beta-catenin leads to elongated spines and impaired synaptic transmission. The beta-catenin-PSD-95 interaction is particularly important for maintaining spine stability and synaptic strength[@tao2008].
Synaptic plasticity: Beta-catenin is required for long-term potentiation (LTP) and long-term depression (LTD), forms of synaptic plasticity underlying learning and memory. NMDA receptor activation modulates beta-catenin localization and signaling, creating a feedback loop between synaptic activity and beta-catenin function[@inestrosa2013].
Neurotransmitter release: Pre-synaptic beta-catenin regulates vesicle docking and neurotransmitter release at excitatory synapses through its interactions with synaptic vesicle proteins and active zone components.
Beta-catenin signaling is critical for neural stem cell proliferation and differentiation in the adult brain[@sun2020]:
Multiple lines of evidence implicate dysregulated Wnt/beta-catenin signaling in Alzheimer's disease pathogenesis[@palomer2019][@henriques2006]:
Amyloid-beta interaction with Wnt signaling: [Amyloid-beta](/proteins/amyloid-beta) peptides directly bind to Wnt receptors (Frizzled) and inhibit canonical Wnt signaling. This suggests a pathogenic feedback loop where Aβ suppresses neuroprotective Wnt signaling, while reduced Wnt signaling may increase neuronal vulnerability to amyloid toxicity[@magdesian2008].
GSK-3β as a shared pathogenic node: [GSK-3β](/genes/gsk3b), the primary kinase that phosphorylates [tau](/proteins/tau) protein leading to neurofibrillary tangle formation, also phosphorylates beta-catenin. This links two major pathogenic mechanisms in AD: amyloid accumulation and tau pathology[@hernandez2012].
Synaptic dysfunction: Reduced beta-catenin signaling contributes to synaptic dysfunction and loss in AD brains. Post-mortem studies show decreased beta-catenin levels in the hippocampus of AD patients, particularly in regions vulnerable to early neurofibrillary pathology.
Therapeutic potential: Small molecules that activate Wnt/beta-catenin signaling, such as Wnt agonists and GSK-3β inhibitors (including lithium), have shown promise in AD mouse models, improving cognitive function and reducing amyloid pathology[@de2011].
Neurogenesis impairment: Wnt/beta-catenin signaling is critical for hippocampal neurogenesis. Its impairment contributes to the decline in neural stem cell function observed in AD, potentially exacerbating memory deficits.
Beta-catenin dysfunction in [Parkinson's disease](/diseases/parkinsons-disease) relates to multiple mechanisms[@berwick2017]:
Dopaminergic neuron survival: Wnt/beta-catenin signaling is critical for the development and survival of dopaminergic neurons in the substantia nigra pars compacta. Dysregulation contributes to progressive dopaminergic neurodegeneration, the hallmark of PD[@prakash2006].
Alpha-synuclein pathology: Beta-catenin degradation is enhanced in PD models with [alpha-synuclein](/proteins/alpha-synuclein) overexpression, suggesting a pathogenic interaction between these proteins. Restoring beta-catenin levels may protect against alpha-synuclein toxicity.
Mitochondrial dysfunction: Beta-catenin regulates mitochondrial biogenesis and function through transcriptional control of PGC-1α and other mitochondrial regulators. Its dysregulation may exacerbate mitochondrial defects characteristic of PD[@goddard2017].
Neuroinflammation: Wnt signaling modulates microglial activation and neuroinflammatory responses. Dysregulated beta-catenin signaling in glial cells may contribute to neuroinflammation in PD.
In [ALS](/diseases/als), Wnt/beta-catenin signaling is altered in motor neurons and supporting glial cells[@chen2014]:
The Wnt/beta-catenin pathway represents a promising therapeutic target for neurodegenerative diseases:
Wnt agonists: Small molecule activators of Wnt signaling (e.g., CHIR99021) have shown neuroprotective effects in cellular and animal models of AD and PD. These compounds inhibit GSK-3β activity, stabilizing beta-catenin.
GSK-3β inhibitors: Lithium and other GSK-3β inhibitors prevent beta-catenin degradation and have been investigated for AD and PD therapy. Lithium's mood-stabilizing effects may involve Wnt pathway modulation.
Beta-catenin stabilizers: Peptide-based approaches to stabilize beta-catenin and enhance transcriptional activation without overactivating oncogenic pathways.
Frizzled receptor modulators: Agonists targeting specific Frizzled receptors expressed in the brain may provide tissue-specific activation.
CTNNB1 is widely expressed throughout the brain with highest levels in regions critical for learning and memory[@shimizu2005]:
| Brain Region | Expression Level | Cell Type |
|--------------|-----------------|-----------|
| Hippocampus (CA1-CA3) | Very High | Pyramidal neurons |
| Dentate Gyrus | High | Granule cells |
| Cerebral Cortex | High | Pyramidal neurons (L2/3, L5) |
| Cerebellum | Moderate | Purkinje cells |
| Subventricular Zone | High | Neural stem cells |
| Substantia Nigra | Moderate | Dopaminergic neurons |
Expression is enriched at synaptic membranes, reflecting the protein's role in synaptic function. Beta-catenin is also expressed in glial cells, where it modulates astrocyte and oligodendrocyte function.
Beta-catenin interacts with numerous proteins relevant to neurodegeneration:
| Partner | Interaction Type | Relevance |
|---------|-----------------|-----------|
| GSK-3β | Phosphorylation | Coregulates stability |
| TCF/LEF | Transcriptional | Gene regulation |
| N-cadherin | Adhesion | Synaptic structure |
| PSD-95 | Signaling | Synaptic plasticity |
| APC | Destruction complex | Protein degradation |
| AXIN | Destruction complex | Protein degradation |
| α-catenin | Adhesion | Cytoskeletal linking |
The relationship between beta-catenin and GSK-3β represents a critical node in neurodegenerative disease pathogenesis[@hernandez2012]:
Reciprocal regulation: GSK-3β phosphorylates beta-catenin on N-terminal serine/threonine residues, targeting it for proteasomal degradation. Conversely, beta-catenin can inhibit GSK-3β activity through direct protein-protein interactions, creating a regulatory loop.
Shared downstream targets: Both proteins regulate tau phosphorylation, with GSK-3β directly phosphorylating tau and beta-catenin influencing the expression and activity of tau kinases.
Therapeutic implications: GSK-3β inhibitors used in AD therapy (such as lithium) work in part by stabilizing beta-catenin, restoring Wnt signaling, and reducing tau pathology simultaneously.
Beta-catenin cross-talks with Notch signaling pathways[@wasson2024]:
Beta-catenin is phosphorylated by PKA, which can enhance its transcriptional activity:
While germline CTNNB1 mutations are primarily associated with cancer and developmental disorders, somatic mutations and expression alterations are relevant to neurodegeneration:
Somatic mutations: Analysis of AD brain tissue reveals somatic CTNNB1 mutations in some cases, though these are less common than in cancer.
Expression alterations: Multiple studies report decreased CTNNB1 expression in AD and PD brain tissue, particularly in affected regions.
Single nucleotide polymorphisms: GWAS studies have identified CTNNB1 variants associated with increased risk for AD and PD, though the functional significance requires further study.
Individuals with Down syndrome (trisomy 21) have an extra copy of the APP gene (located on chromosome 21) and often develop early-onset AD pathology. The role of CTNNB1 (on chromosome 3) in this context:
Beta-catenin and related proteins have potential as biomarkers:
Peripheral markers: Studies have detected Wnt pathway protein alterations in cerebrospinal fluid and blood of AD and PD patients.
Brain imaging: PET tracers targeting beta-catenin pathway components are under development.
Therapeutic response: Beta-catenin pathway activation may serve as a biomarker for Wnt-targeting therapeutic efficacy.
| Model | Description | Application |
|-------|-------------|-------------|
| Nestin-Cre;CTNNB1 flox/flox | Neuron-specific knockout | Synaptic function |
| CamKII-Cre;CTNNB1 flox/flox | Excitatory neuron knockout | Learning/memory |
| hAPP transgenic;CTNNB1oe | APP x beta-catenin OE | Amyloid interaction |
| MPTP;CTNNB1ko | PD model in KO mice | Dopaminergic function |
Several Wnt-targeting strategies are being explored:
The following diagram shows the key molecular relationships involving CTNNB1 — Catenin Beta 1 discovered through SciDEX knowledge graph analysis: